References
- Bancalari E, Claure N, Gonzalez A. Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 2005;88:192-201. https://doi.org/10.1159/000087582
- Clyman RI. Ductus arteriosus: current theories of prenatal and postnatal regulation. Semin Perinatol 1987;11:64-71.
- Heymann MA, Rudolf AM. Control of the ductus arteriosus. Physiol Rev 1975;55:62-78. https://doi.org/10.1152/physrev.1975.55.1.62
- Clyman RI. Mechanisms regulating the ductus arteriosus. Biol Neonate 2006;89:330-5. https://doi.org/10.1159/000092870
- Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995;126:605-10. https://doi.org/10.1016/S0022-3476(95)70362-4
- Kluckow M, Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr 2000;137:68-72. https://doi.org/10.1067/mpd.2000.106569
- Hammerman C. Patent ductus arteriosus: clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol 1995;22:457-79.
- Cotton RB, Stahlman MT, Kovar I, Catterton WZ. Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr 1978;92:467-73. https://doi.org/10.1016/S0022-3476(78)80451-X
- Walther FJ, Benders MJ, Leighton JO. Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics 1992;90:899-904.
- Flynn PA, da Graca RL, Auld PA, Nesin M, Kleinman CS. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005;147:38-42. https://doi.org/10.1016/j.jpeds.2005.03.040
- Holmstrom H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 2001;90:184-91. https://doi.org/10.1111/j.1651-2227.2001.tb00282.x
- Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50: 2357-68. https://doi.org/10.1016/j.jacc.2007.09.021
- Cantinotti M, Clerico A, Murzi M, Vittorini S, Emdin M. Clinical relevance of measurement of brain natriuretic peptide and N-terminal probrain natriuretic peptide in pediatric cardiology. Clin Chim Acta 2008; 390:12-22. https://doi.org/10.1016/j.cca.2007.12.020
- Reynolds EW, Ellington JG, Vranicar M, Bada HS. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004;114:1297-304. https://doi.org/10.1542/peds.2004-0525
- Puddy VF, Amirmansour C, Williams AF, Singer DR. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond) 2002;103:75-7. https://doi.org/10.1042/CS20020046
- Attridge JT, Kaufman DA, Lim DS. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2009;94:F178-82.
- Evans N. Diagnosis of patent ductus arteriosus in the preterm newborn. Arch Dis Child 1993;68(1 Spec No):58-61. https://doi.org/10.1136/adc.68.1_Spec_No.58
- Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echochardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health 1994;30:406-11. https://doi.org/10.1111/j.1440-1754.1994.tb00689.x
- Skinner J. Diagnosis of patent ductus arteriosus. Semin Neonatol 2001; 6:49-61. https://doi.org/10.1053/siny.2000.0037
- Tammela O, Ojala R, Iivainen T, et al. Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. J Pediatr 1999;134:552-7. https://doi.org/10.1016/S0022-3476(99)70239-8
- El Hajjar M, Vaksmann G, Rakza T, Kongolo G, Storme L. Severity of the ductal shunt: a comparison of different markers. Arch Dis Child Fetal Neonatal Ed 2005;F90:419-22.
- Young TE, Mangum B. Neofax: a Manual of Drugs Used in Neonatal Care. 20th ed. Montvale, NJ: Thompson Healthcare; 2007.
- Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8. https://doi.org/10.1056/NEJM199807303390507
- Da Graca RL, Hassinger DC, Flynn PA, Sison CP, Nesin M, Auld PA. Longitudinal changes of brain-type natriuretic peptide in preterm neonates. Pediatrics 2006;117;2183-9. https://doi.org/10.1542/peds.2005-1387
- Lee HS, Choi WS, Choi BM, et al. Usefulness of B-type natriuretic peptide assay in predicting symptomatic patent ductus arteriosus in preterm infants. J Korean Soc Neonatol 2004;11:44-53.
- Choi BM, Lee KH, Eun BL, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005;115:e255-61. https://doi.org/10.1542/peds.2004-1837
- Hsu JH, Yang SN, Chen HL, Tseng HI, Dai ZK, Wu JR. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus. J Pediatr 2010;157:79-84. https://doi.org/10.1016/j.jpeds.2009.12.045
- Tomaru Ki K, Arai M, Yokoyama T, et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002;34:649-59. https://doi.org/10.1006/jmcc.2002.2005
- Ueda S, Nishio K, Akai Y, et al. Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock. Shock 2006;26:134-9. https://doi.org/10.1097/01.shk.0000226266.99960.d0
- El-Khuffash A, Molloy EJ. Are B-type natriuretic peptide (BNP) and Nterminal- pro-BNP useful in neonates? Arch Dis Child Fetal Neonatal Ed 2007;92:F320-4. https://doi.org/10.1136/adc.2006.106039
Cited by
- Clinical Applications of Plasma B-type Natriuretic Peptide Assays in Preterm Infants with Patent Ductus Arteriosus vol.20, pp.3, 2013, https://doi.org/10.5385/nm.2013.20.3.323
- Diagnosing Significant PDA Using Natriuretic Peptides in Preterm Neonates: A Systematic Review vol.135, pp.2, 2012, https://doi.org/10.1542/peds.2014-1995
- Brain Natriuretic Peptide: It’s Not About the Brain or Just Another Smart Polypeptide—It’s About the Heart vol.34, pp.6, 2012, https://doi.org/10.1891/0730-0832.34.6.355
- The role of n terminal - probrain natriuretic peptide in the diagnosis of hemodynamic persistent asrteriosus ductus in premature neonates patient vol.884, pp.None, 2017, https://doi.org/10.1088/1742-6596/884/1/012147
- Effectiveness of B-type Natriuretic Peptide in Caring for Preterm Infants vol.29, pp.2, 2018, https://doi.org/10.14734/pn.2018.29.2.78
- The Role of Natriuretic Peptides in Management of Premature Infants with Hemodynamically Significant Patent Arterial Duct vol.18, pp.1, 2019, https://doi.org/10.15690/vsp.v18i1.1987
- Early prediction of spontaneous Patent Ductus Arteriosus (PDA) closure and PDA-associated outcomes: a prospective cohort investigation vol.19, pp.1, 2019, https://doi.org/10.1186/s12887-019-1708-z
- B-natriuretic peptide serum levels in neonates with persistent pulmonary hypertension vol.69, pp.None, 2012, https://doi.org/10.1186/s43054-021-00058-y
- Application of B-Type Natriuretic Peptide in Neonatal Diseases vol.9, pp.None, 2012, https://doi.org/10.3389/fped.2021.767173